Copernicus Group IRB Enter Strategic Alliance with IRB Services in Canada
Research Triangle Park, NC and Aurora, ON Canada - September 7, 2010 - Copernicus Group IRB (CGIRB), a leading independent institutional review board, today announced a new strategic alliance with IRB Services of Canada. This partnership will enable CGIRB to offer institutional review services to its clients whose clinical research protocols include Canadian sites. The objective of this alliance is to provide CGIRB clients a single solution for ethical review of clinical research protocols and sites in North America.
Each client will work with a dedicated CGIRB single point of contact with team support bridging both IRBs. The integrated team will ensure an expeditious and thorough ethical review and quality client service in full compliance with regulatory and ethical requirements in both countries.
“This alliance will benefit both organizations by providing a seamless service to CGIRB clients who plan to include Canadian sites in addition to US research,” said Jack Corman, CEO and Founder of IRB Services. “I am delighted to be partnering with Copernicus Group IRB, one of the leading independent IRBs in the United States.”
This new alliance, coupled with with CGIRB’s ISO 9001:2008 certification, AAHRPP accreditation, and existing corporate partnerships, will expand on CGIRB’s commitment to protect the rights and welfare of human subjects by providing innovative service offerings and quality review.
“We are pleased to provide this new offering to our clients who have requested additional service extending into Canada. It supports our dedication to superior quality and innovation,” said Bruce Tomason, CEO of CGIRB. “IRB Services is a highly regarded independent institutional review board with deep and insightful understanding of the Canadian research regulatory and ethical landscape nationally and in every province of the country. This alliance will further enhance our shared mission of human subject protection.”
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
